Naveed Mariam, Malik Ayesha, Anjum Hamza, Ijaz Bushra
Centre of Excellence in Molecular Biology, University of the Punjab, 87-West Canal Road Thokar Niaz Baig , Lahore, 53700, Pakistan.
Laboratory of Applied and Functional Genomics, Centre of Excellence in Molecular Biology (CEMB), University of the Punjab, 87-West Canal Bank Road, Lahore, 53700, Pakistan.
Biochem Genet. 2024 Oct;62(5):3421-3438. doi: 10.1007/s10528-023-10592-6. Epub 2023 Dec 18.
Breast cancer is a significant health challenge for women globally, including the Pakistani population. Numerous pathways and small molecules like noncoding ribonucleotides are implicated in breast cancer development and progression. Among these, lncRNAs, have garnered considerable attention due to their role in breast cancer tumorigenesis and metastasis. In the current study involving 52 mammary tumor samples from the Pakistani population, the expression of lncRNA MALAT1 (metastasis associated lung adenocarcinoma transcript 1) was studied via RT-PCR (Real-Time polymerase chain reaction). In addition, PI3K/AKT/mTOR pathway expression was also assessed through RT-PCR and immunohistochemistry in breast cancer patient samples. The study also investigated the cross-talk of lncRNA MALAT1 and PI3K pathway genes by inhibiting it with PI3K inhibitor (LY294002) in MDA-MB-231 cell line. Furthermore, lncRNA MALAT1 was silenced in MDA-MB-231 cells using siRNA to determine its impact on breast cancer proliferation and metastasis. The results revealed an upregulated expression of MALAT1 and PI3K/AKT/mTOR pathway genes in grade II and III breast tissue samples before chemotherapy. The proliferation, growth, and invasion of breast cancer cells were significantly reduced upon MALAT1 silencing in MDA-MB-231. Further, its downregulation substantially reduced the PI3K pathway expression levels at mRNA and protein levels. In conclusion, the current study suggests that MALAT1 could serve as a therapeutic target for breast cancer, underscoring its role in breast cancer proliferation and metastasis. Moreover, the study proposes a mechanism of action of MALAT1, demonstrating that its inhibition can reduce the expression of the PI3K/AKT/mTOR axis. These findings emphasize the potential significance of targeting MALAT1 as a therapeutic strategy for breast cancer, and further exploration of this interaction is warranted to gain deeper insight into the molecular mechanism of this lncRNA.
乳腺癌是全球女性面临的重大健康挑战,包括巴基斯坦人群。众多途径和小分子如非编码核糖核苷酸与乳腺癌的发生和发展有关。其中,长链非编码RNA(lncRNAs)因其在乳腺癌肿瘤发生和转移中的作用而备受关注。在这项涉及52例巴基斯坦人群乳腺肿瘤样本的研究中,通过逆转录聚合酶链反应(RT-PCR)研究了lncRNA MALAT1(转移相关肺腺癌转录本1)的表达。此外,还通过RT-PCR和免疫组化对乳腺癌患者样本中的PI3K/AKT/mTOR途径表达进行了评估。该研究还在MDA-MB-231细胞系中用PI3K抑制剂(LY294002)抑制lncRNA MALAT1,研究其与PI3K途径基因的相互作用。此外,使用小干扰RNA(siRNA)使MDA-MB-231细胞中的lncRNA MALAT1沉默,以确定其对乳腺癌增殖和转移的影响。结果显示,化疗前II级和III级乳腺组织样本中MALAT1和PI3K/AKT/mTOR途径基因表达上调。在MDA-MB-231细胞中沉默MALAT1后,乳腺癌细胞的增殖、生长和侵袭明显减少。此外,其下调显著降低了mRNA和蛋白质水平上的PI3K途径表达水平。总之,本研究表明MALAT1可作为乳腺癌的治疗靶点,突出了其在乳腺癌增殖和转移中的作用。此外,该研究提出了MALAT1的作用机制,表明其抑制可降低PI3K/AKT/mTOR轴的表达。这些发现强调了靶向MALAT1作为乳腺癌治疗策略的潜在意义,有必要进一步探索这种相互作用,以更深入地了解这种lncRNA的分子机制。